A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis

Trial Profile

A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Siponimod (Primary)
  • Indications Dermatomyositis; Polymyositis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top